Back to Home
Video

Module 1: Plenary 1

Release Date

April 30, 2026

Expiration Date

May 1, 2027

Credits

2.75 CME, NCPD

Specialties

Breast Cancer

Activity Overview

This educational activity is an archive of the live conference held on March 5-8, 2026.

Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management.

Learning Objectives

  • Incorporate the latest best practices for genomic and molecular testing to optimize risk stratification and timely identification of actionable alterations in patients with breast cancer
  • Apply recent innovations in imaging modalities alongside new surgical approaches and radiation therapy techniques to improve the locoregional management of patients with breast cancer
  • Evaluate the clinical implications of key findings from recent pivotal trials across early-stage and metastatic breast cancers
  • Develop individualized treatment plans for patients with breast cancer based on the latest clinical data and expert guidance
Module 1: Plenary 1

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exact Sciences, Inc; Lilly USA, LLC; Novartis Pharmaceuticals; and Puma Biotechnology, Inc.

Follow Us on Social Media!

Related Content

Course

Module 1: Plenary 1

Create Account